Industry Cost Structure Must Change, But Will Not Start At AstraZeneca – CEO
Executive Summary
AstraZeneca CEO Tom McKillop called on the pharmaceutical industry to reduce the costs associated with selling and marketing drugs, but does not believe his company will be the catalyst for change
You may also be interested in...
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
Quality Not Quantity: Pfizer Cuts Sales Team To Increase Meaningful Contacts
Pfizer's decision to reduce its sales force reflects a change in the company's marketing strategy, but does not mean the firm is facing a shortage of products to support, according to CEO Jeffrey Kindler
AstraZeneca’s Gut Instinct: CEO-Designate Is Nexium Brand Builder Brennan
AstraZeneca is elevating an executive integral to the commercial success of the company's proton pump inhibitor franchise with the appointment of U.S. head David Brennan as CEO